(NASDAQ: SGMT) Sagimet Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Sagimet Biosciences's earnings in 2026 is -$43,512,000.On average, 13 Wall Street analysts forecast SGMT's earnings for 2026 to be -$69,725,643, with the lowest SGMT earnings forecast at -$90,540,546, and the highest SGMT earnings forecast at -$14,776,012. On average, 13 Wall Street analysts forecast SGMT's earnings for 2027 to be -$74,669,336, with the lowest SGMT earnings forecast at -$107,929,128, and the highest SGMT earnings forecast at -$39,188,552.
In 2028, SGMT is forecast to generate -$83,859,219 in earnings, with the lowest earnings forecast at -$131,913,379 and the highest earnings forecast at -$54,606,999.